G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Size Projected To Increase From $0.78 Billion To $2.42 Billion During The Forecast Period
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
#G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Size And Revenue Forecast Through 2030
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market has seen significant expansion in its size over recent years. This market is projected to expand from $0.59 billion in 2025 to $0.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 32.7%. The growth observed historically is largely attributable to advancements in targeted cancer therapy research, an increasing prevalence of multiple myeloma cases, the expansion of monoclonal antibody development programs, improvements in clinical trial infrastructure, and rising investments in oncology drug discovery.
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market is set for significant expansion in the coming years, with projections indicating it will reach $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 32.9%. This projected growth during the forecast period is primarily fueled by a surge in regulatory approvals for targeted biologics, the escalating demand for individualized cancer treatments, the ongoing development of next-generation immunotherapy platforms, increased financial commitments to precision medicine ecosystems, and the wider adoption of biomarker-guided therapy selection. Key developments expected during this timeframe involve the accelerating creation of bispecific antibody therapies, an intensifying focus on gprc5d biomarker-informed patient screening, the broadened use of CAR-T cell platforms, an expansion in precision oncology clinical trial pipelines, and the enhanced incorporation of companion diagnostics.
Download A Free Sample Report For Comprehensive Market Insights:
G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Industry Drivers: What Is Driving Revenue Growth?
An increase in myeloma prevalence is projected to boost the expansion of the GPRC5D-targeted therapies market in the future. Myeloma, a cancer affecting plasma cells within the bone marrow, interferes with the regular production of blood cells and may lead to issues such as bone damage, anemia, and kidney dysfunction. The occurrence of myeloma is growing, partly attributable to aging demographics, given that the likelihood of developing plasma cell disorders increases with age as genetic mutations accrue over time. GPRC5D-targeted therapies provide a treatment approach for myeloma by attaching to the GPRC5D protein found on malignant plasma cells and guiding the immune system, particularly T cells, to specifically eliminate these cancerous cells, largely preserving healthy ones. For example, in January 2026, the American Cancer Society, a US-based professional organization, reported expectations for 2026 that the United States will see around 36,000 new cases of multiple myeloma, with 20,150 cases in men and 15,850 cases in women, and an anticipated 10,850 deaths, consisting of 5,780 men and 5,070 women. Consequently, the increasing prevalence of myeloma is propelling the expansion of the GPRC5D-targeted therapies market.
G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Segment Analysis And Revenue Opportunities
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market covered in this report is segmented –
1) By Therapy Type: Monoclonal Antibodies; Bispecific Antibodies; Chimeric Antigen Receptor (CAR-T) Cell Therapies; Other Therapy Types
2) By Indication: Multiple Myeloma; Solid Tumors; Other Indications
3) By Technology: Precision Medicine Approaches; Molecular Targeted Therapy; Cancer Immunotherapy Platforms; Biopharmaceutical Drug Delivery Systems
4) By Route Of Administration: Intravenous; Subcutaneous; Other Routes Of Administration
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies
2) By Bispecific Antibodies: Dual Targeting Bispecific Antibodies; Cross Linking Bispecific Antibodies; Immune Cell Engaging Bispecific Antibodies; Cytotoxic Bispecific Antibodies
3) By Chimeric Antigen Receptor (CAR-T) Cell Therapies: Autologous Car T Cell Therapies; Allogeneic Car T Cell Therapies; Next Generation Car T Cell Therapies; Gene Edited Car T Cell Therapies
4) By Other Therapy Types: Targeted Small Molecule Drugs; Receptor Specific Inhibitors; Injectable Biologics; Oral Targeted Therapeutics
#G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Growth Trends: What Is Influencing The Future Outlook?
Leading companies in the GPRC5D targeted therapies market are concentrating on developing innovative solutions, such as bispecific T cell engagers, to enhance immune-mediated targeting of cancer cells and improve treatment effectiveness. A bispecific T-cell engager (BiTE) is a type of immunotherapy molecule engineered to connect T-cells directly to cancer cells through simultaneous binding, thereby activating the T-cells to eliminate the specified cancer cells. For instance, in August 2023, Johnson & Johnson, a US-based healthcare company, secured approval from the European Commission for TALVEY (talquetamab), Janssen’s bispecific antibody therapy targeting GPRC5D, intended for relapsed and refractory multiple myeloma (RRMM) in patients who have received at least three prior therapies. This is a first-in-class bispecific T-cell engager that targets GPRC5D on multiple myeloma cells and CD3 on T cells for treating relapsed/refractory multiple myeloma in heavily pretreated patients. Its main goal is to provide durable responses (ORR >70% in trials) after at least four prior therapies, with advantages including subcutaneous dosing, sustained quality-of-life benefits, and efficacy even after bispecifics or CAR-T, thus addressing an unmet need in late-line disease.
G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Leading Players Shaping Industry Direction
Major companies operating in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market are Johnson And Johnson, F. Hoffmann-La Roche AG., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Bristol Myers Squibb Company, Genmab A/S, Genentech Inc., Simcere Zaiming Biotechnology Co. Ltd., Innovent Biologics Inc., Essen Biotech Co. Ltd., Nanjing IASO Biotechnology Co. Ltd., CARsgen Therapeutics Holdings Limited, Oricell Therapeutics Co. Ltd., Integral Molecular Inc., Overland Therapeutics Inc., Qilu Pharmaceutical Co. Ltd., Leads Biolabs Ltd., ShanghAI Yake Biotechnology Co. Ltd., Guangzhou Bio-gene Technology Co. Ltd.
Access The Complete G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Report:
#G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the GPRC5D targeted therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
